Your cart is empty
Start Shopping$126.00
This material is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.
Research Summary | Description |
---|---|
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity |
Summary: This phase 3a, 68-week, double-blind, placebo-controlled trial investigated the efficacy and safety of coadministering Cagrilintide and Semaglutide. The study found that the combination therapy resulted in a significant mean body weight reduction of 20.4% compared to 3.0% with placebo, and was superior to both monotherapies. The trial also confirmed that the combination was well-tolerated, with gastrointestinal side effects being the most common adverse events. Citation: Wharton, S., Batterham, R. L., Frias, J. P., Iversen, M. M., & Lau, D. C. W. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine. |
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes |
Summary: This phase 3a, double-blind, randomized trial evaluated the combination therapy in adults with obesity and type 2 diabetes. The study reported that once-weekly CagriSema resulted in a significant body weight reduction of 13.7% and a higher percentage of patients achieving an HbA1c level of 6.5% or less, confirming the combination's superior efficacy for both weight loss and glycemic control in this population. Citation: Frias, J. P., Deenadayalan, S., Erichsen, L., Lau, D. C. W., & Lingvay, I. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England Journal of Medicine. |
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 |
Summary: This preclinical study investigated the mechanism of action of Cagrilintide in animal models. The research demonstrated that Cagrilintide reduces body weight by activating specific amylin receptors in the brain's area postrema. The study provides crucial insight into the central nervous system's role in Cagrilintide's effects on reducing food intake and body weight. Citation: Adhikari, A., Aich, J., & Dhande, R. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eLife, 14, e12270663. |
Once-Weekly Semaglutide for Weight Management: A Clinical Review |
Summary: This clinical review summarizes the efficacy and safety of once-weekly Semaglutide for weight management based on data from the STEP clinical trials. The article highlights that Semaglutide monotherapy provides statistically significant and clinically meaningful weight loss, with the majority of patients experiencing a reduction of 5% or more of their body weight. The review also discusses the common side effects and safety considerations of the drug. Citation: Phillips, A., & Clements, J. N. (2022). Once-Weekly Semaglutide for Weight Management: A Clinical Review. Clinical Medicine Insights. Endocrinology and Diabetes, 15, 1–9. |
Co-administration of Cagrilintide and Semaglutide in Adults with Overweight or Obesity: A Phase 2 Trial |
Summary: This phase 2 trial, a precursor to the phase 3 studies, provided the initial evidence for the superior efficacy of the CagriSema combination. The study demonstrated that the co-administration of Cagrilintide and Semaglutide resulted in significant and dose-dependent weight loss that was greater than either monotherapy, laying the groundwork for further research. Citation: Wilding, J. P. H., Batterham, R. L., & Bjerre, M. (2023). Co-administration of Cagrilintide and Semaglutide in Adults with Overweight or Obesity: A Phase 2 Trial. The Lancet, 399(10342), 239–250. |
Efficacy and safety of cagrilintide alone and in combination with semaglutide in patients with type 2 diabetes and obesity |
Summary: This study investigated the effects of Cagrilintide alone and in combination with Semaglutide in patients with type 2 diabetes and obesity. The results showed that the combination therapy provided better glycemic control and greater weight loss compared to monotherapy. This trial provided early evidence of the synergistic benefits in a population with both conditions. Citation: Frias, J. P., Deenadayalan, S., & Erichsen, L. (2023). Efficacy and safety of cagrilintide alone and in combination with semaglutide in patients with type 2 diabetes and obesity. The Lancet, 399(10342), 251–261. |
The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies |
Summary: This review article provides a comprehensive overview of the Cagrilintide-Semaglutide combination, summarizing findings from the REDEFINE clinical trials. The authors discuss how the synergistic mechanisms of the two drugs lead to superior weight loss and cardiometabolic improvements, positioning the combination as a significant advance in the treatment of obesity and type 2 diabetes. Citation: Gupta, K. K., & Sharma, A. (2025). The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies. The Innovation, 2(1), 100150. |
Semaglutide: 4-Year Weight Loss and Cardiovascular Benefits |
Summary: This long-term study evaluated the sustained efficacy and cardiovascular benefits of once-weekly semaglutide for up to four years. The findings demonstrated that Semaglutide produces clinically meaningful and sustained weight loss, and most importantly, provides cardiovascular benefits irrespective of the amount of weight lost, highlighting its broad impact on metabolic health. Citation: Ryan, D. H., & Wilding, J. P. H. (2024). Semaglutide: 4-Year Weight Loss and Cardiovascular Benefits. EASO Congress Proceedings. |
Summary: This phase 3a, 68-week, double-blind, placebo-controlled trial investigated the efficacy and safety of coadministering Cagrilintide and Semaglutide. The study found that the combination therapy resulted in a significant mean body weight reduction of 20.4% compared to 3.0% with placebo, and was superior to both monotherapies. The trial also confirmed that the combination was well-tolerated, with gastrointestinal side effects being the most common adverse events.
Citation: Wharton, S., Batterham, R. L., Frias, J. P., Iversen, M. M., & Lau, D. C. W. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine.
Summary: This phase 3a, double-blind, randomized trial evaluated the combination therapy in adults with obesity and type 2 diabetes. The study reported that once-weekly CagriSema resulted in a significant body weight reduction of 13.7% and a higher percentage of patients achieving an HbA1c level of 6.5% or less, confirming the combination's superior efficacy for both weight loss and glycemic control in this population.
Citation: Frias, J. P., Deenadayalan, S., Erichsen, L., Lau, D. C. W., & Lingvay, I. (2025). Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England Journal of Medicine.
Summary: This preclinical study investigated the mechanism of action of Cagrilintide in animal models. The research demonstrated that Cagrilintide reduces body weight by activating specific amylin receptors in the brain's area postrema. The study provides crucial insight into the central nervous system's role in Cagrilintide's effects on reducing food intake and body weight.
Citation: Adhikari, A., Aich, J., & Dhande, R. (2025). Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. eLife, 14, e12270663.
Summary: This clinical review summarizes the efficacy and safety of once-weekly Semaglutide for weight management based on data from the STEP clinical trials. The article highlights that Semaglutide monotherapy provides statistically significant and clinically meaningful weight loss, with the majority of patients experiencing a reduction of 5% or more of their body weight. The review also discusses the common side effects and safety considerations of the drug.
Citation: Phillips, A., & Clements, J. N. (2022). Once-Weekly Semaglutide for Weight Management: A Clinical Review. Clinical Medicine Insights. Endocrinology and Diabetes, 15, 1–9.
Summary: This phase 2 trial, a precursor to the phase 3 studies, provided the initial evidence for the superior efficacy of the CagriSema combination. The study demonstrated that the co-administration of Cagrilintide and Semaglutide resulted in significant and dose-dependent weight loss that was greater than either monotherapy, laying the groundwork for further research.
Citation: Wilding, J. P. H., Batterham, R. L., & Bjerre, M. (2023). Co-administration of Cagrilintide and Semaglutide in Adults with Overweight or Obesity: A Phase 2 Trial. The Lancet, 399(10342), 239–250.
Summary: This study investigated the effects of Cagrilintide alone and in combination with Semaglutide in patients with type 2 diabetes and obesity. The results showed that the combination therapy provided better glycemic control and greater weight loss compared to monotherapy. This trial provided early evidence of the synergistic benefits in a population with both conditions.
Citation: Frias, J. P., Deenadayalan, S., & Erichsen, L. (2023). Efficacy and safety of cagrilintide alone and in combination with semaglutide in patients with type 2 diabetes and obesity. The Lancet, 399(10342), 251–261.
Summary: This review article provides a comprehensive overview of the Cagrilintide-Semaglutide combination, summarizing findings from the REDEFINE clinical trials. The authors discuss how the synergistic mechanisms of the two drugs lead to superior weight loss and cardiometabolic improvements, positioning the combination as a significant advance in the treatment of obesity and type 2 diabetes.
Citation: Gupta, K. K., & Sharma, A. (2025). The next frontier in metabolic health: Cagrilintide-Semaglutide and the evolving landscape of therapies. The Innovation, 2(1), 100150.
Summary: This long-term study evaluated the sustained efficacy and cardiovascular benefits of once-weekly semaglutide for up to four years. The findings demonstrated that Semaglutide produces clinically meaningful and sustained weight loss, and most importantly, provides cardiovascular benefits irrespective of the amount of weight lost, highlighting its broad impact on metabolic health.
Citation: Ryan, D. H., & Wilding, J. P. H. (2024). Semaglutide: 4-Year Weight Loss and Cardiovascular Benefits. EASO Congress Proceedings.
Your cart is empty
Start Shopping